Reports related to this article:
Plant(s): View 1 related plant in PECWeb
Released June 23, 2020 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--U.K. pharmaceutical major AstraZeneca has pledged to supply Europe with up to 400 million doses of the University of Oxford's COVID-19 vaccine at no profit and with deliveries starting by the end of this year.
The company has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, for Oxford University's AZD1222. The recombinant adenovirus vaccine technology was created by the Jenner Institute at the University. The vaccine began its Phase II/III U.K. trial in about 10,000 adult volunteers last month and other late-stage trials are due to begin in a number of countries with the goal of having up to 30,000 volunteers. AstraZeneca recently completed similar agreements with the U.K., U.S., the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance, for 700 million doses, and it agreed a licence with the Serum Institute of India for the supply of an additional 1 billion doses, principally for low- and middle-income countries. Total manufacturing capacity currently stands at 2 billion doses.
Pascal Soriot, chief executive officer of AstraZeneca, said: "This agreement will ensure that hundreds of millions of Europeans have access to Oxford University's vaccine following approval. With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response."
Last week he told Belgian radio: "We think that it will protect for about a year. If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well."
Dutch health minister Hugo de Jonge, representing the IVA, commented: "This is an important step that we're taking today. A vaccine is crucial in combating the virus. Until we have a vaccine, it will flare up time and again. That's why everyone's working so hard to develop one. We believe in the power of cooperation, and we're also hedging our bets because you never know which horse is going to win the race."
This week AstraZeneca announced that it has teamed up with Catalent Biologics to provide vial-filling and packaging capacity for AZD1222 at its manufacturing facility in Anagni, Italy. Catalent said that will prepare the 28,000 square-meter (305,000 square-foot) facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of the vaccine candidate from August 2020, and potentially through to March 2022 "should the product be approved by regulatory agencies."
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
Plant(s) 3297292
The company has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, for Oxford University's AZD1222. The recombinant adenovirus vaccine technology was created by the Jenner Institute at the University. The vaccine began its Phase II/III U.K. trial in about 10,000 adult volunteers last month and other late-stage trials are due to begin in a number of countries with the goal of having up to 30,000 volunteers. AstraZeneca recently completed similar agreements with the U.K., U.S., the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance, for 700 million doses, and it agreed a licence with the Serum Institute of India for the supply of an additional 1 billion doses, principally for low- and middle-income countries. Total manufacturing capacity currently stands at 2 billion doses.
Pascal Soriot, chief executive officer of AstraZeneca, said: "This agreement will ensure that hundreds of millions of Europeans have access to Oxford University's vaccine following approval. With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response."
Last week he told Belgian radio: "We think that it will protect for about a year. If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well."
Dutch health minister Hugo de Jonge, representing the IVA, commented: "This is an important step that we're taking today. A vaccine is crucial in combating the virus. Until we have a vaccine, it will flare up time and again. That's why everyone's working so hard to develop one. We believe in the power of cooperation, and we're also hedging our bets because you never know which horse is going to win the race."
This week AstraZeneca announced that it has teamed up with Catalent Biologics to provide vial-filling and packaging capacity for AZD1222 at its manufacturing facility in Anagni, Italy. Catalent said that will prepare the 28,000 square-meter (305,000 square-foot) facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of the vaccine candidate from August 2020, and potentially through to March 2022 "should the product be approved by regulatory agencies."
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
Plant(s) 3297292
